Azacitidine and Enasidenib for IDH-2 Mutations

Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome

What's the purpose of the trial?

This phase II trial studies the side effects and how well azacitidine and enasidenib work in treating patients with IDH2-mutant myelodysplastic syndrome. Azacitidine and enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Trial status

Accepting patients

Phase

Phase 2

Enrollment

Last Updated

1 month ago

Patient Screener

For Healthcare Professionals Only

This site is intended for healthcare professionals in the US. Patients and care partners can explore and connect with MDS clinical trials through our patient portal.

View Patient Portal

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

Azacitidine is a type of chemotherapy called a hypomethylating agent that interferes with the growth and spread of cancer cells in the body.
Enasidenib is an IDH2 inhibitor that is FDA approved to treat acute myeloid leukemia in patients with a specific IDH2 mutations, and being studied for use in other blood cancers.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Arm A: Enasidenib + Azacitidine

Accepting patients

Arm B: Enasidenib

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.